OncoSec Medical Down Premarket on $11.2 Million Share, Warrant Offering

Dow Jones

Feb 02, 2023

By Rob Curran

Shares of biotech company OncoSec Medical Inc. plunged premarket after it arranged to sell $11.2 million in shares and warrants in a follow-on offering.

In a Securities and Exchange Commission filing, OncoSec said it planned to sell 6.2 million common shares and warrants that would represent a further 6.2 million shares, priced at $2.02 apiece.

The developer of immunotherapy treatments for cancer estimates it will raise $11.2 million from the offering, which it plans to use for general corporate purposes, including research and development and potential merger-and-acquisition deals.

Shares of OncoSec, which last raised $3.5 million in a November share offering, fell 28% to $1.54 premarket.

Write to Rob Curran at rob.curran@wsj.com

(END) Dow Jones Newswires

February 02, 2023 08:39 ET (13:39 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2308025929"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2308025929\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2308025929?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-02-02 21:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2308025929","market":"hk","top_or_hot":-1,"title":"OncoSec Medical Down Premarket on $11.2 Million Share, Warrant Offering","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of biotech company OncoSec Medical Inc. plunged premarket after it arranged to sell $11.2 million in shares and warrants in a follow-on offering. \n</p>\n<p>\n  In a Securities and Exchange Commission filing, OncoSec said it planned to sell 6.2 million common shares and warrants that would represent a further 6.2 million shares, priced at $2.02 apiece. \n</p>\n<p>\n  The developer of immunotherapy treatments for cancer estimates it will raise $11.2 million from the offering, which it plans to use for general corporate purposes, including research and development and potential merger-and-acquisition deals. \n</p>\n<p>\n  Shares of OncoSec, which last raised $3.5 million in a November share offering, fell 28% to $1.54 premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n   Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2023 08:39 ET (13:39 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OncoSec Medical Down Premarket on $11.2 Million Share, Warrant Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOncoSec Medical Down Premarket on $11.2 Million Share, Warrant Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2023-02-02 21:39</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Rob Curran \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of biotech company OncoSec Medical Inc. plunged premarket after it arranged to sell $11.2 million in shares and warrants in a follow-on offering. \n</p>\n<p>\n  In a Securities and Exchange Commission filing, OncoSec said it planned to sell 6.2 million common shares and warrants that would represent a further 6.2 million shares, priced at $2.02 apiece. \n</p>\n<p>\n  The developer of immunotherapy treatments for cancer estimates it will raise $11.2 million from the offering, which it plans to use for general corporate purposes, including research and development and potential merger-and-acquisition deals. \n</p>\n<p>\n  Shares of OncoSec, which last raised $3.5 million in a November share offering, fell 28% to $1.54 premarket. \n</p>\n<pre>\n \n</pre>\n<p>\n   Write to Rob Curran at rob.curran@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 02, 2023 08:39 ET (13:39 GMT)\n</p>\n<p>\n  Copyright (c) 2023 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2308025929","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2308025929","pubTimestamp":1675345140,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"By Rob Curran \n\n\n \n\n\n  Shares of biotech company OncoSec Medical Inc. plunged premarket after it arr","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"OncoSec Medical盘前股价下跌1120万美元，认股权证发行","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ONCS":1},"content_text":"By Rob Curran \n\n\n \n\n\n  Shares of biotech company OncoSec Medical Inc. plunged premarket after it arranged to sell $11.2 million in shares and warrants in a follow-on offering. \n\n\n  In a Securities and Exchange Commission filing, OncoSec said it planned to sell 6.2 million common shares and warrants that would represent a further 6.2 million shares, priced at $2.02 apiece. \n\n\n  The developer of immunotherapy treatments for cancer estimates it will raise $11.2 million from the offering, which it plans to use for general corporate purposes, including research and development and potential merger-and-acquisition deals. \n\n\n  Shares of OncoSec, which last raised $3.5 million in a November share offering, fell 28% to $1.54 premarket. \n\n\n \n\n\n   Write to Rob Curran at rob.curran@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 02, 2023 08:39 ET (13:39 GMT)\n\n\n  Copyright (c) 2023 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}